VSVictor M. Santana

Victor M. Santana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victor M. Santana has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world implementation, feasibility and early effectiveness of blinatumomab for pediatric B-ALL in lower-middle-income countries

    by Caitlyn Duffy, Zehra Fadoo, Niharendu Ghara, Lan Ngoc Bui, Gaurav Narula, Aqeela Rashid, Muhammad Rafie Raza, Linh T. D. Pham, Hilmarie Muniz-Talavera, Yichen Chen, et al.

    In 2025, blinatumomab was added to the World Health Organization Essential Medicines List for Children for the treatment of B-cell acute lymphoblastic leukemia (B-ALL); yet access remains limited in many low- and middle-income countries (LMICs). Consequently, real-world experience in these settings, particularly in those in which access, supportive care, and delivery infrastructure differ substantially from those in high-income countries, remains poorly characterized. To evaluate the early effectiveness and implementation challenges of blinatumomab administration for pediatric B-ALL in LMICs, an observational cohort study was conducted at 6 pediatric oncology centers participating in a blinatumomab drug-access program in India, Pakistan, and Vietnam. A consecutive sample of 106 children aged 1 to 18 years with relapsed/refractory B-ALL (n = 60 [56.6%]) or minimal residual disease (MRD) >0.1% (n = 46 [43.4%]) received blinatumomab. Across 192 cycles, 54 unplanned interruptions occurred, primarily due to adverse events. Severe (grade ≥3) cytokine release syndrome occurred in 2 patients during cycle 1; severe neurotoxicity occurred in 4 patients in cycle 1 and 1 in cycle 2. Among 71 patients with follow-up data, 26 (36.6%) subsequently received a hematopoietic stem cell transplant (HSCT), including 14 for relapsed/refractory disease. Six-month event-free survival (EFS) and overall survival (OS) were 61.5% ± 5.8% and 89.9% ± 3.6%, respectively, and 12-month EFS and OS were 58.1% ± 7.1% and 82.8% ± 5.5%, respectively. Survival did not differ significantly by HSCT status. MRD-negative status after cycle 1 was associated with superior 12-month EFS (P< .0001) and OS (P = .0366). With implementation support, blinatumomab was safely and effectively delivered in pediatric referral centers in LMICs, supporting strategies to broaden immunotherapy access globally.

  • Open Access

    Development of a conceptual framework for stigma in pediatric cancer

    by Lara E. Counts, Sara Malone, Nele Loecher, Kayla Wynja, Douglas A. Luke, I‐Chan Huang, Victor Santana, Tara Brinkman, Dylan E. Graetz

    Introduction: Stigma in pediatric cancer contributes to negative psychosocial outcomes and can impede health‐seeking behavior. Existing stigma frameworks are limited, often focusing on specific regions, diagnoses, and adult populations, with none designed for pediatric cancer. Developing a framework that reflects the experiences of patients with pediatric cancer and their caregivers is essential to advance research and inform policy. Methods: A literature search of stigma tools across behavioral or physical health conditions was followed by concept mapping to develop a pediatric cancer stigma framework. Stigma‐related statements were extracted, refined for clarity, and used to prepopulate a concept mapping exercise. Multidisciplinary global participants, including experts in stigma, measurement development, pediatric oncology, and individuals with lived experience (survivors and caregivers), sorted and rated statements. An expert panel further refined identified concepts. Results: A total of 5299 patient‐related and 216 caregiver‐related statements were identified and reduced to 74 and 93 statements, respectively, for sorting and rating. Participants completed the concept mapping activities (patients: n = 46; caregivers: n = 26). Five key stigma domains were identified for patients (perceived stigma, internalized stigma, family influence, discrimination experiences, and community systems/organizations) and caregivers (perceived stigma, anticipated stigma, internalized stigma, discrimination experiences, and organizational discrimination). Conclusion: This framework highlights the key components of stigma across the treatment continuum. Informed by the collaborative voices of experts, researchers, survivors, and caregivers, this framework highlights key areas that should be examined, measured, and intervened upon to mediate the impact of stigma on this vulnerable population.

  • Navigating the Planning and Initiation of a First Prospective Clinical Trial Through a Regional Pediatric Oncology Consortium Within the Middle East, Africa, and Asia—A Roadmap

    by Ruzanna Papyan, Farah Ghamloush, Iman Sidhom, Asim Belgaumi, Rihab Nasr, Iyad Sultan, Gevorg Tamamyan, Venkatraman Radhakrishnan, Carlos Rodriguez‐Galindo, Sima Jeha, et al.

    Background: Prospective pediatric oncology clinical trials remain scarce across low‐ and middle‐income countries (LMICs). We developed the first multicountry prospective clinical trial within the Pediatric Oncology East and Mediterranean (POEM) group. Localized osteosarcoma was selected due to heterogeneous real‐world management, including alternative regimens in settings where methotrexate administration is not feasible. This descriptive report details the feasibility of a regionally coordinated, resource‐adapted clinical trial across diverse LMIC settings. Methods: We describe the planning, capacity assessment, training, governance, and activation of POEM‐OS, a pragmatic two‐arm prospective cohort study evaluating MAP‐ and OS99‐based therapy for localized osteosarcoma. Preparation included a structured capacity‐mapping exercise across regional centers to assess clinical resources, research, and regulatory structures. The approach also encompassed designing a training program and communication through a structured study coordination team. Results: A total of 27 centers from 10 countries expressed intent to participate. A 12‐week virtual training curriculum was implemented for principal investigator and clinical research coordinator dyads, followed by an in‐person regional workshop. Eventually, 21 centers (8 countries) proceeded to study activation. Major barriers included heterogeneity in chemotherapy administration, high staff turnover, and variability in timelines to study‐agreement execution. Adaptive solutions included permanently accessible online training modules, simplified chemotherapy dosing, and harmonized toxicity grading. Centralized REDCap platforms enabled regional data sharing. By February 2026, the study had opened at 16 centers, with 21 patients enrolled. Conclusion: POEM‐OS demonstrates that a regionally directed, resource‐adapted clinical trial platform is feasible across diverse LMIC settings and establishes a foundation for sustainable regional clinical research infrastructure.

  • Clinical Research Capacity Building in Pediatric Oncology in Resource-Limited Settings: Application and Early Results of Regional Educational Workshops

    by Raya Saab, Rihab Nasr, Iman Sidhom, Asim Belgaumi, Meenakshi Devidas, Paula Naidu, Vaskar Saha, Iyad Sultan, Paola Friedrich, Mariam Fanous, et al.

    PURPOSE: The global need for training in clinical research is substantial, particularly in resource-limited settings. We describe an international collaboration to build capacity in clinical research skills through a semi-personalized curriculum. METHODS: Five sequential workshops (2020-2025) combined online modules with on-site, project-based learning. The curriculum across workshops included research project planning, proposal writing, and manuscript publishing. Topics included fundamentals of clinical study design, data registries, statistical considerations, research ethics, and scientific writing. At registration, applicants submitted an abstract for further development. An average of 35 applicants per workshop were selected. Participants' experiences were evaluated through postworkshop surveys. RESULTS: Participants across the workshops presented from 17 countries and seven disciplines, with the majority being physicians (66%) and nurses (16%). During each 2.5-day workshop, participants refined their abstracts with structured guidance and shared their work in a 10-minute presentation. Workshop 1 used a group-based model where each group developed one common Workshop 2 focused on quality improvement research; each group worked on preselected mock concepts through a structured learning exercise. Workshops 3 and 4 involved individualized learning, with each participant developing their own abstract into a study proposal. Workshop 5 focused on scientific writing, guiding participants to develop their abstracts into a manuscript outline. Surveys after each workshop consistently demonstrated a high level of satisfaction and perceived gain in knowledge and skill. CONCLUSION: These workshops effectively engaged trainees with various levels of clinical research training and imparted skills for research planning and manuscript writing. Future iterations will include thematic workshops including advanced statistical methods. Combining asynchronous learning modules with on-site, project-based training can be implemented across other regions and specialties in context-relevant settings.

  • Open Access

    Mapping integrated implementation of Adapted Resource and Implementation Application (ARIA) and REDCap version hospital-based pediatric cancer registry (HBCR) in Ethiopia: An implementation Study

    by Diriba Fufa Hordofa, Yohannes Kebede, Mamude Dinkye, Tadele Hailu, Zewdie Birhanu, Megan C. Roberts, Victor Santana, Nickhill Bhakta

    This study presents the perceived implementability of the digital Hospital-Based Cancer Registry (HBCR) and the Adapted-Resource Implementation Application (ARIA) to enhance data systems and treatment standards at Pediatric Oncology unit (POU). A 2-year (2023–2025) implementation study on the integrated application of ARIA and HBCRs is being conducted at Jimma University Medical Center (JUMC) and St. Paul Hospital Millennium Medical College (SPHMMC). This article reports the formative assessment results, guided by the Consolidated Framework for Implementation Research (CFIR), involved eight focus group discussions, four in-depth interviews, and two co-design workshops with diverse healthcare providers and hospital management/leadership personnel. The integrated implementation of HBCR-ARIA was viewed as innovative and adaptable. Digital HBCR was perceived as more effective than manual methods for managing pediatric oncology data. Similarly, ARIA was perceived as effective and feasible for providing patient-specific standardized care. Workflows and responsibilities were co-defined separately for the respective POUs. The co-designed implementation strategy includes residents filling demographic and diagnostic information of patients’ on HBCR interim document and then cross-checked by the pediatric Hematology and Oncology (PHO) fellows. The Medical Monitor (PHO senior) approves the validity of the document before entry into REDCap by the data clerk. ARIA is filled by PHO fellows and approved by second PHO fellow or PHO seniors based on the availability. Facilitators in both the inner (hospital) and outer (external) settings outweighed the barriers. Facilities and motivated human resources are in place to implement the digital HBCR and ARIA strategies at the respective POU. However, challenges such as inconsistent electric power, unreliable internet services, and logistic-supply issues. The implementation strategies for digitized HBCR and ARIA, co-designed to fit the specific contexts of two POU, appear promising but require further evaluation.


  • Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium

    by Priya Kumar, Monika L. Metzger, John K. Choi, Godwin Job, Teresa C. Santiago, Armando Peña, Miguela A. Caniza, Asya Agulnik, Pascale Y. Gassant, Wendy C. Gómez García, et al.

    PURPOSE: Clinical and histopathologic diagnosis of pediatric mature B-cell lymphomas (eg, Burkitt lymphoma [BL]) must be accurate to select appropriate risk-based treatment. The Central American Pediatric Hematology-Oncology Association (AHOPCA) in 2000 implemented standardized, resource-adapted treatments for these lymphomas. We evaluated the concordance of local histopathologic diagnoses through central review, determined the impact on therapy selection, and described the clinical characteristics and outcomes of pediatric patients with these lymphomas. We suggest recommendations to improve the accuracy of diagnoses. METHODS: Pathology samples and reports were submitted by six AHOPCA sites to St Jude Children's Research Hospital for central review. The concordance of sample assessments was evaluated using three criteria: histologic diagnosis, morphology, and immunohistochemistry. Clinical characteristics, treatment, and outcomes were also analyzed. RESULTS: Of the 68 eligible patients, 53 (78%) received an accurate pathologic diagnosis of BL. For nine (13%) patients, diagnoses changes with therapy implications were made upon central review, while in six patients, there was a minor disagreement with no therapy implications. Most (87%) patients presented with advanced disease. Detailed cellular features were absent in many reports, and immunohistochemistry was routinely performed at only one site. Of the 50 patients whose treatment data were reported, 44 (88%) completed therapy, five died during treatment, and one abandoned treatment. Treatment outcome was satisfactory: 3-year event-free survival was 74% (SE ± 11%), and overall survival was 73% (SE ± 11%). CONCLUSION: Pathology laboratories in limited-resource hospitals and regions need further optimization to increase accurate diagnoses of mature B-cell lymphomas. Creating regional pathology networks will enhance diagnostic support. Despite resource limitations and advanced disease at presentation, the AHOPCA sites' adapted treatment strategies have improved patient outcomes.